Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For going through this torture, I would like to see the CEO dinner with the shareholders be at Berns Steakhouse, compliments of UATG. <grin>
Correct about VNDM.
I see the 10k blocks traded by VNDM.
I also see a few MM signals to each other. Wish I knew their signals...like the 666 trade I see here from time to time.
The O/S has increased....updated on OTC Markets.
Yesterday's VNDM appearance increased the O/S to 383,783,339
An increase of 10 million shares.
May not have seen VNDM first in line on the Ask but it was low enough to do its thing. Is usually evident by the 10k block transactions.
Since they are redesigning their tPEMF devices, do you know if the MS study will be the first to go into action?
The MS study will be using the patented wearable device from RGN, I would assume.
Or will the external ventricular drain (EVD) study in an intensive care unit (ICU) setting start soon? What device was to be used with this study? Is this one requiring a redesigned TPEMF device?
If ENDV is redesigning the Theracap, seems we will be hearing of a new patent application in the future.
It appeared so. Declining SP is our pattern these days.
Another pattern of late is a PR weekly.
Hoping for the heart PR this week.
New Form 4 released.
If Mann is continuing to purchase....keep the faith!!!
Observation. Between this Form 4 and the previous, there is a skipped day of purchase. Friday Jan 19.
PR about Europe sales came out on Monday Jan 22.
Does the skipped day have anything to do with the PR? Don't know. Just continuing to make the observations of the skipped days and the PRs in proximity to those days.
Detailed heart results will be out soon. Endonovo said "early Q1". We have past 4 weeks of Q1. 2 more weeks and we are at mid Q1. Then we will have past the "early" stage.
Soooooo...maybe we get results within the week.
Positive vibes people!!!!!
It appears dilution is happening today. VNDM is hanging out low on the Ask today and I see 10k transactions occurring.
I tried looking in post history with "acorn" terminology. There was some talk March last year.
I did not find any post that stated it was false though.
If it's not true, why would Acorn continue to list ENDV as a client?
It could be possible ENDV was once a client but their website is not making a differentiation of current and past clients if that is the case.
If they do as they say...will be good for us.
"The AMP process has consistently delivered an increase in the number of shareholders, market capitalization, as well as the company’s funding opportunities and institutional ownership."
Anybody know something about Endonovo being a client of Acorn Management?
www.acornmanagementpartners.com/clients/otc-clients
Why is the Actipatch allowed to be sold over the counter without a prescription?
Aside from physical differences, the PEMF difference between Actipatch and Sofpulse seem to be with the pulse rate and pulse duration.
Sofpulse has a longer pulse duration.
Does this have anything to do with needing Dr. assistance?
While we wait for ENDV to release further heart data results, here is some info from a study done in 2014 examining whether PEMF therapy facilitate cardiac recovery in rat myocardial infarction (MI)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058309/
We are banking on that being a catalyst to boost SP.
That headline has a familiar ring to it.
http://www.otcmarkets.com/stock/ENDV/news/Endonovo-Signs-Term-Sheet-for--5-Million-to-Redeem-All-Outstanding-Convertible-Notes-and-Prepare-to-Uplist-Its-Common-Stock?id=145801&b=y
It did nothing significant to the stock price back in Nov 2016.
Hope this time will be different.
According to this study it is 27.12 mhz.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317147/
What do you know about Regenesis Biomedical and their Provant Therapy device? They are using PEMF 27.12 mhz to treat pain.
It is mentioned in the Twitter link Endonovo sent out today.
The formatting of your message is not very readable on my phone.
Is that the January 2015 presentation?
I used that presentation to reference the Drs and locations that ENDV may be using for their concussion clinicals.
In what timeframe do you think they can move to human trials on the heart?
I've tried to generate interest on the concussion side. Almost everyone here needs to learn to embrace that and Sofpulse. Immunotronics with the organs is going to be a longer wait than most thought it would take.
It seems you have had to evolve and adapt to the changing focus of the company and yet you still remain positive.
When you first invested, the company was mostly about Cytotronics. Now they have basically shelved it.
Thanks for the answer. I was pretty much thinking the same (the heart being an easier organ to work on). I think of it as a muscle as opposed to a filter with the filtration process being more complex, hence why even pharmaceutical companies haven't hit success yet.
I believe a liver pre-clinical success would be much bigger news than the heart.
Do you have insight as to why ENDV started studying the liver back in April 2015, then switched gears to the heart in Dec 2016? And then back to the liver afterwards?
I would think they are well advanced with the research on that organ and would not be taking as long to come to a conclusion. Unless it's just not an easy organ and they keep hammering on it without giving up.
BMIC is on the Ask today.
Can forget about any upward movement in the meantime.
You can go to OTCmarkets.com and look them up in the company search field.
ADM Tronics Unlimited
Then look at the financial filings.
Were you Bid sitting? It shows as a sell because someone sold into your Bid.
The 2 transactions are part of the total sale you see around that time. It was not exact ( a little more) as it must have been combined with another order.
You can look at ADM Tronics financials. They are a public traded company that manufacturers the Sofpulse. They do not mention specific customers though.
Under the Engineering Services aspect in their financials you can see "The decrease in the engineering division is primarily the result of decreased sales volume from one customer. "
I suspect that customer is Rio Grande.
Please tell me in what PR states that?
The corporate update PR states "...upon the redesign of its tPEMF devices for use in CNS disorders."
They have 3 concussion clinicals planned. You are most likely correct about the Theracap technology being redesigned and used in them. But that may apply to 2 of the 3.
The Theracap clinical trial was all setup and ready to go.
Did RGN discover something flawed with it? Did ENDV find something flawed with it during negotiations?
I will admit, when I saw it, it looks like a hokey invention.
Sofpulse is not involved with the upcoming concussion trials.
I can say with certainty the Theracap will be used at the clinical study in the post concussion study at Spaulding hospital.
Thanks to this document, I have made a NFL connection.
Dr. Hunt Batjer was going to work with Rio Grande on a concussion study. Dr. Barker works at UT Southwestern, a location for a future clinical trial listed in this document.
Dr. Barker is a co-chair of NFL head, neck, and spine medical committee.
I would assume he will oversee the Endonovo acute concussion syndrome clinical trial.
http://profiles.utsouthwestern.edu/profile/133473/hunt-batjer.html
I have no idea on the delay for the heart.
I could write a bunch of speculative comments but that's all it would be.
I would imagine ENDV is getting some sales recognition in the US from repeat orders from established customers Rio Grande had.
It seems RGN had declining sales though. ENDV needs to ramp up the sales force again. RGN used independent sales consultants with commission margins.
They need to hit the pavement and go knocking on doors.
The most recent PR from ENDV states they are "seeking distribution partners in Europe for SofPulse"
That is great news. We are expanding our potential customer base.
It seems too soon after the conference to have a financing deal agreed upon.
I would also think the heart pre clinical data would be a leveraging item. We have not seen it released yet.
Since it has slowed down in here, I'll post something to spark new conversation.
With the Sofpulse being marketed in Europe, I wanted to know which country could use it more. One of the marketed use of Sofpulse is for the recovery after breast surgery.
Here is a list of the top 10 countries for breast augmentation. 5 are in Europe.
1. United States
2. Brazil
3. Mexico
4. Germany
5. Spain
6. Colombia / Venezuela
7. Russia
8. Canada
9. United Kingdom
10. Greece
Looks like ENDV needs to put some feet on ground in Brazil and Mexico as well.
The Form 4 released today has 1 missing day of purchase.
There was no significant PR around that date though.
Jan 12 - no purchase date
Jan 11 - ShareIntel PR
Jan 16 - Corporate Update PR
Jan 22 - Europe Sofpulse sales PR
Looking at the Form 4, he did have a 2k and 1k purchase on Jan 11.
Jan 12 had none though.
What would your estimated month be for hearing preliminary results on the other organs being tested with Immunotronics?
The heart was a 6 month testing period (re-start in March with new signal to Sept/Oct).
The starting timeframe for the other organs is not clear for me. They made PRs in May and June but then seemed to state in the Sept PR they were commencing at that time.
If we were sitting idle, I would not blame you. But there are many iron in the fire now. I think it would be a bad move to leave at a loss now (unless you have a "sure thing" to move to).
Sofpulse is covered for chronic ulcers (wounds). It does not have Medicare coverage for back pain.
Biotech told me out Sofpulse tech is licensed to Assisi.
I would think ENDV is Now getting a cut of the action. Would only make sense.
It's our patent.
I do not have my notes on the dates in which i saw a span of 5 trading days but I have been tracking since Jan 2017. I recall that was the longest span between Form 4 filings.
Today we have hit the 6th trading day since the last Form 4 on Jan 12. This is the longest gap I have noticed since the last Form 4 was filed.
Is Mann done buying?
Is there BIG news coming?
Inquiring minds want to know!!!!
One thing that confuses me is this statement on the Form 4.
"This Form must be filed before the end of the second business day following the day on which a transaction resulting
in a change in beneficial ownership has been executed...."
As described above, I have seen a few gaps of 5 trading days (business days) in which there was continuous buying.
So was ENDV out of compliance in those filings?
Not that I or anyone here cares. Just an observation.
You put it into better perspective with your statement "the most patients that need it are covered. The % increases with age."
So who cares if the young demographic can't be covered. The money is with the geriatric demographics.
We are golden!!!
Sofpulse is a prescription device and cannot be sold directly to patients.
Below is a link to the site.
http://sofpulse.com/how-to-get-sofpulse.php
Actually, even though CMS covers Sofpulse, regular insurance companies for the general public, do not cover Sofpulse expense.
See the link below on how UnitedHealthcare rationalized not covering it.
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.uhcprovider.com/content/dam/provider/docs/public/policies/medicaid-comm-plan/electrical-stimulation-electromagnetic-therapy-wounds-cs.pdf&ved=2ahUKEwjSosLag-7YAhVmdt8KHadLBH8QFjABegQIEBAB&usg=AOvVaw0lbtsM0llFWgKuET7UkTdl
On the positive side, we have the baby boomer generation at the CMS coverage age. Could see potential uptick in sales for the older folks.